Zealand Pharma A/S (OTCMKTS:ZLDPF) Announces Quarterly Earnings Results, Misses Expectations By $0.66 EPS

Key Points

• Zealand Pharma A/S reported a quarterly earnings per share (EPS) of $16.06, with a negative return on equity of 13.40% and a staggering negative net margin of 2,127.09%.
• The company's share price increased by 1.0% to $54.03, with a market cap of $3.84 billion and current and quick ratios of 25.10 and 25.07, respectively.
• Several analysts, including BNP Paribas and Barclays, have upgraded Zealand Pharma A/S to a "strong-buy" rating, reflecting positive investor sentiment towards the stock.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $16.06 earnings per share for the quarter, missing the consensus estimate of $16.72 by ($0.66), Zacks reports. The business had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%.

Zealand Pharma A/S Stock Up 6.1%

Shares of Zealand Pharma A/S stock traded up $3.50 during trading on Tuesday, hitting $61.00. 1,804 shares of the stock were exchanged, compared to its average volume of 563. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The firm's 50-day moving average price is $57.53 and its 200 day moving average price is $70.34. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of 4.28 and a beta of 0.71. Zealand Pharma A/S has a 12-month low of $49.98 and a 12-month high of $136.76.

Analysts Set New Price Targets

Several analysts recently issued reports on ZLDPF shares. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Zacks Research lowered shares of Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a report on Friday. Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Finally, BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Five equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Zealand Pharma A/S presently has an average rating of "Buy".

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.